The Challenge of Crystal Growth
To understand the future of space manufacturing, we first need to look at proteins. Our bodies use them for everything, and they are the key to both diseases and their cures. To design effective drugs, scientists must understand a protein's three-dimensional
structure. The best way to do this is through a process called protein crystallization. By turning a protein into a highly ordered, stable crystal, researchers can analyze its structure with X-rays. The problem is that gravity gets in the way. On Earth, the force of gravity causes sedimentation and convection currents in the solution where crystals grow. This disturbs the delicate formation process, leading to smaller, less perfect, and often flawed crystals. For many important proteins, growing a crystal on Earth that is large and pure enough for detailed analysis is nearly impossible.
The Microgravity Solution
In the near-zero gravity environment of low-Earth orbit, these problems disappear. Without gravity, there is no sedimentation to cause impurities to settle into the crystal, and no convection currents to disrupt the orderly arrangement of molecules. In this stable, diffusion-controlled environment, molecules have the time and space to align perfectly. The result is the growth of larger, more uniform, and structurally perfect biological crystals than can be achieved on the ground. Data from decades of experiments on the Space Shuttle and the International Space Station (ISS) shows that microgravity-grown crystals are superior in almost every metric, including size, uniformity, and the resolution they provide during analysis.
Revolutionizing Drug Development
The ability to create near-perfect protein crystals has profound implications for medicine. A higher-quality crystal allows scientists to map a protein's structure with incredible precision, identifying the exact 'keyholes' a drug needs to fit into. This detailed understanding accelerates the drug discovery process, enabling the design of more effective medications with fewer side effects for diseases ranging from cancer and muscular dystrophy to neurodegenerative disorders. For example, pharmaceutical giant Merck has conducted experiments on the ISS to grow crystals of its cancer drug Keytruda, aiming to develop a version that can be administered as a simple injection instead of an intravenous infusion, making treatment more accessible for patients.
A New Commercial Frontier
For decades, this research was the domain of government space agencies like NASA. Now, a new commercial ecosystem is emerging to capitalize on it. With the ISS set to retire around 2030, private companies are racing to build the next generation of orbiting outposts. Companies like Axiom Space, Vast, and Starlab (a joint venture including Airbus) are developing commercial space stations that will function as orbital research labs and manufacturing hubs. These platforms are being designed specifically to support activities like protein crystallization, with dedicated research and manufacturing modules. Axiom Space, for instance, has already flown multiple private astronaut missions to the ISS, building a research foundation and a pipeline for future biomanufacturing work on its own station.
More Than Just Crystals
While biological crystals for drug development are a primary focus, they are just the beginning of in-space manufacturing. The same principles of microgravity that benefit crystal growth also apply to other advanced materials. Companies are exploring the production of superior semiconductor chips, flawless ZBLAN optical fibers for high-speed communication, and even 3D-printing human tissues and organs for regenerative medicine. The vision is to create an industrial park in low-Earth orbit, where the unique properties of space are leveraged to produce high-value items that are impossible to make on Earth. These products would then be returned to our planet for use, marking a paradigm shift from space exploration to space industrialization.
